110 related articles for article (PubMed ID: 38794892)
1. Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3.
Iida S; Ito S; Yokoyama H; Ishida T; Nagai Y; Handa H; Ito S; Kamei Y; Nakamura M; Suzuki K
Jpn J Clin Oncol; 2024 May; ():. PubMed ID: 38794892
[TBL] [Abstract][Full Text] [Related]
2. Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma.
Costa LJ; LeBlanc TW; Tesch H; Sonneveld P; Kyle RP; Sinyavskaya L; Hlavacek P; Meche A; Ren J; Schepart A; Aydin D; Nador G; DiBonaventura MD
Future Oncol; 2024 Feb; ():. PubMed ID: 38415370
[TBL] [Abstract][Full Text] [Related]
3. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Lesokhin AM; Tomasson MH; Arnulf B; Bahlis NJ; Miles Prince H; Niesvizky R; Rodrίguez-Otero P; Martinez-Lopez J; Koehne G; Touzeau C; Jethava Y; Quach H; Depaus J; Yokoyama H; Gabayan AE; Stevens DA; Nooka AK; Manier S; Raje N; Iida S; Raab MS; Searle E; Leip E; Sullivan ST; Conte U; Elmeliegy M; Czibere A; Viqueira A; Mohty M
Nat Med; 2023 Sep; 29(9):2259-2267. PubMed ID: 37582952
[TBL] [Abstract][Full Text] [Related]
4. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Bahlis NJ; Costello CL; Raje NS; Levy MY; Dholaria B; Solh M; Tomasson MH; Damore MA; Jiang S; Basu C; Skoura A; Chan EM; Trudel S; Jakubowiak A; Gasparetto C; Chu MP; Dalovisio A; Sebag M; Lesokhin AM
Nat Med; 2023 Oct; 29(10):2570-2576. PubMed ID: 37783970
[TBL] [Abstract][Full Text] [Related]
5. Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3.
Mohty M; Bahlis NJ; Nooka AK; DiBonaventura M; Ren J; Conte U
Br J Haematol; 2024 May; 204(5):1801-1810. PubMed ID: 38420657
[TBL] [Abstract][Full Text] [Related]
6. A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma.
Mol I; Hu Y; LeBlanc TW; Cappelleri JC; Chu H; Nador G; Aydin D; Schepart A; Hlavacek P
Curr Med Res Opin; 2024 Feb; 40(2):199-207. PubMed ID: 38078866
[TBL] [Abstract][Full Text] [Related]
7. A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma.
Mol I; Hu Y; LeBlanc TW; Cappelleri JC; Chu H; Nador G; Aydin D; Schepart A; Hlavacek P
Leuk Lymphoma; 2024 May; 65(5):660-668. PubMed ID: 38347747
[TBL] [Abstract][Full Text] [Related]
8. Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos MV; Bahlis N; Popat R; Besemer B; Martínez-López J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ
N Engl J Med; 2022 Aug; 387(6):495-505. PubMed ID: 35661166
[TBL] [Abstract][Full Text] [Related]
9. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
[TBL] [Abstract][Full Text] [Related]
10. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
11. Elranatamab: First Approval.
Dhillon S
Drugs; 2023 Nov; 83(17):1621-1627. PubMed ID: 37924427
[TBL] [Abstract][Full Text] [Related]
12. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Nooka AK; Cohen AD; Lee HC; Badros A; Suvannasankha A; Callander N; Abdallah AO; Trudel S; Chari A; Libby EN; Chaudhry M; Hultcrantz M; Kortüm KM; Popat R; Sborov D; Hakim S; Lewis E; Gorsh B; Bhushan B; McKeown A; Gupta I; Opalinska J; Richardson PG; Lonial S
Cancer; 2023 Dec; 129(23):3746-3760. PubMed ID: 37622738
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).
Jing H; Yang L; Qi J; Qiu L; Fu C; Li J; Yang M; Qi M; Fan N; Ji J; Lu J; Li Y; Jin J
Ann Hematol; 2022 Dec; 101(12):2679-2690. PubMed ID: 36301338
[TBL] [Abstract][Full Text] [Related]
14. Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma.
Rais T; Khan A; Riaz R
Rare Tumors; 2023; 15():20363613231207483. PubMed ID: 37840703
[TBL] [Abstract][Full Text] [Related]
15. A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
Cornell RF; Bishop MR; Kumar S; Giralt SA; Nooka AK; Larson SM; Locke FL; Raje NS; Lei L; Dong J; Le Gall JB; Rossi JM; Orlowski RZ
Am J Cancer Res; 2021; 11(6):3285-3293. PubMed ID: 34249462
[TBL] [Abstract][Full Text] [Related]
16. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
Qiu L; Xia Z; Fu C; Chen W; Chang C; Fang B; An G; Wei Y; Cai Z; Gao S; Weng J; Chen L; Jing H; Li F; Liu Z; Chen X; Liu J; Wang A; Yu Y; Xiang W; Lynch K; Yu Z; Fu W
BMC Med; 2022 Apr; 20(1):108. PubMed ID: 35379237
[TBL] [Abstract][Full Text] [Related]
17. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
D'Souza A; Shah N; Rodriguez C; Voorhees PM; Weisel K; Bueno OF; Pothacamury RK; Freise KJ; Yue S; Ross JA; Polepally AR; Talati C; Lee S; Jin Z; Buelow B; Vij R; Kumar S
J Clin Oncol; 2022 Nov; 40(31):3576-3586. PubMed ID: 36029527
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
Sunami K; Fuchida SI; Suzuki K; Ri M; Matsumoto M; Shimazaki C; Asaoku H; Shibayama H; Ishizawa K; Takamatsu H; Ikeda T; Maruyama D; Imada K; Uchiyama M; Kiguchi T; Iyama S; Murakami H; Onishi R; Tada K; Iida S
Hematol Oncol; 2023 Aug; 41(3):442-452. PubMed ID: 36433829
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
